728 results on '"Masters, C. L."'
Search Results
2. Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials
3. Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer’s Continuum
4. Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
5. A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer’s Disease
6. Association Between Cognitive Function and Clustered Cardiovascular Risk of Metabolic Syndrome in Older Adults at Risk of Cognitive Decline
7. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease using Cerebrospinal Fluid Biomarkers in the AIBL Study
8. Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study
9. The Role of the Extracellular Matrix in Regulating the Function of the Amyloid Protein Precursor of Alzheimer’s Disease
10. Amyloid βA4 of Alzheimer’s Disease: Structural Requirements for Folding and Aggregation
11. Strategic Thoughts on the Alzheimer’s Disease Amyloid Protein Precursor: The Way Forward
12. A[Beta] Deposits in Older Non-Demented Individuals with Cognitive Decline Are Indicative of Preclinical Alzheimer's Disease
13. Alzheimer’s Disease: Physiological and Pathogenetic Role of the Amyloid Precursor Protein (APP), its Aβ-Amyloid Domain and Free Aβ-Amyloid Peptide
14. The Natural History of Alzheimer’s Disease: Minding the Gaps in Understanding the Mechanisms of Neurodegeneration
15. Proteolytic Processing of the Amyloid Precursor Protein of Alzheimer’s Disease
16. Genetic Basis of Resistance to Alzheimer’s Disease and Related Neurodegenerative Diseases
17. Autoxidation of Amyloid Precursor Protein and Formation of Reactive Oxygen Species
18. Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment
19. Dietary patterns and cognitive decline in an Australian study of ageing
20. An anemia of Alzheimer's disease
21. Ethical Considerations in Presymptomatic Testing for Variant CJD
22. A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study
23. Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease
24. Cerebrovascular disease, Alzheimerʼs disease biomarkers and longitudinal cognitive decline: OR2
25. Expression of Alzheimer’s Amyloid Gene in Development, Aging, and Alzheimer’s Disease
26. Unravelling the Molecular Defect in Alzheimer’s Disease
27. Molecular Pathology and Aetiology of Alzheimer’s Disease
28. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimerʼs disease
29. Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing
30. Improved locomotor function and survival of mice with increased levels of mutant superoxide dismutase 1: O03-4
31. HIGHER AB BURDEN IN HEALTHY APOE-E4 CARRIERS IS ASSOCIATED WITH SUBJECTIVE MEMORY COMPLAINTS: RESULTS FROM THE FLUTEMETAMOL AND PIB AIBL COHORTS: O40
32. DETECTION OF PRODROMAL ALZHEIMERʼS DISEASE WITH 18F-FLORBETABEN IMAGING: A PROSPECTIVE OUTCOME STUDY: O37
33. Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests
34. A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease.
35. Copper Modulation of Ion Channels of PrP[106–126] Mutant Prion Peptide Fragments
36. CLINICAL AND BIOMARKER CHANGES IN DOMINANTLY INHERITED ALZHEIMERʼS DISEASE: P01-04
37. IMAGING AND COGNITIVE BIOMARKERS AS PREDICTORS OF PROGRESSION TO ALZHEIMERʼS DISEASE: O38
38. A TWO-YEAR LONGITUDINAL ASSESSMENT OF Aβ DEPOSITION IN MCI WITH 18F-FLORBETABEN: O35
39. Incidence and associations of lobar microbleeds: Results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL): S14 Session 14: Oral Presentations 3 May 2012 1415-1430 Oral Presentation 27
40. Generating recombinant C-terminal prion protein fragments of exact native sequence
41. It all sticks together—the APP-related family of proteins and Alzheimer's disease
42. THE MECHANISM OF ACTION OF METAL-LIGAND COMPLEXES AS POTENTIAL THERAPEUTICS TO TREAT NEURODEGENERATIVE DISEASE: YIC06-02
43. 14-3-3 protein detection and sporadic CJD: the status quo serves well while awaiting progress
44. THE MOLECULAR MECHANISM OF ACTION FOR METAL-LIGAND COMPLEXES AS POTENTIAL THERAPEUTICS FOR ALZHEIMERʼS AND OTHER NEURODEGENERATIVE DISEASES
45. 11C-PiB PET studies in typical sporadic Creutzfeldt–Jakob disease
46. MODULATING COPPER BIO-AVAILABILITY TO TREAT NEURODEGENERATIVE DISEASES: YIC06-01
47. THE GLYCINE RICH REGION OF THE PRION PROTEIN IS A DOMINANT MODULATOR OF PRION INFECTIVITY: S11-04
48. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography
49. Identification of the Alzheimerʼs disease amyloid precursor protein (APP) and its homologue APLP2 as essential modulators of glucose and insulin homeostasis and growth#
50. Packaging of prions into exosomes is associated with a novel pathway of PrP processing
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.